Journal of Cardiovascular Disease Research
Clinical value of interleukin - 6 as a potential biomarker for bronchogenic carcinoma: A clinical study
Dr. Dimple Makhija , Dr. Nabeel Ahmed Hashmi , Dr. Goutham Phani Pulavarthi , Dr. Dushyant Pal Singh
JCDR. 2024: 1600-1604
Abstract
Background: Bronchogenic carcinoma, a predominant form of lung cancer, continues to challenge diagnostic modalities with its late detection and poor prognosis. Interleukin-6 (IL6), a cytokine involved in inflammatory and immune responses, has recently been scrutinized for its potential role as a biomarker in various cancers. This clinical study evaluates the clinical value of IL-6 levels in patients with bronchogenic carcinoma, aiming to establish its utility in early diagnosis and prognosis estimation.
» PDF